Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for sharing. Overall I would call this a positive review of Daxxify! He has only injected himself so he has very limited experience compared to some other injectors who have posted on TikTok or Instagram. His Daxi is still going strong at 4.5 months which is longer than he gets from any of the other toxins! He's waiting to see how long it goes before recommending it to patients, given the price difference.
Also per his comments on difference in spread, that's exactly why RVNC needs to train injectors! Unfortunately the single approved indication limits what RVNC can actually show the injectors how to do, but I'd guess "suggestions" are made in the training sessions that would apply more broadly for injectors to develop techniques they can apply to other muscles.
Jbog is also wrong to assume most big players on Wall Street are run like Axe Cap. In fact, most buy-side fund managers are just follow-the-trend dumb money. WSB is often smarter. And of course sell-side is beyond useless.
WorstLuck is a shill here to spread RVNC FUD. Jbog didn't do snooping. He linked to an anonymous review site. You can go there and read the reviews yourself. They are mostly beyond useless anonymous blurbs. I have been doing actual snooping on Instagram and TikTok for several months and I'd say Daxi favorability is 80-90%. When I have more time I will put together some links, although many posts have already been shared here.
Probably because some people here have suspect motives and aren't transparent about them. Opposing viewpoints are great and if somebody is short a stock I'm long that's fine. But some people are here to troll or pretend to be interested in a stock only to spread FUD.
I've seen realself.com before and it's highly suspect. First of all the sample size is tiny so even if they are all legit reviews it doesn't mean much. But most of the reviews are just anonymous and could be literally anybody (Abbvie shills?). As everybody here knows there are a lot of doubters and people out to spread Revance/Daxxify FUD! I've been following posts about Daxxify on Instagram and TikTok where people mostly post with a legitimate social media identity not some anonymous handle on a random review site. What I've seen there has been overwhelmingly positive. Some people have complianed of overpaying but that is an issue with their injector of choice, not Revance or Daxxify per se.
Couldn't have said it better myself! WorstLuck has a history of making such "observational" statements that are really just his opinion. I suspect he is a fake bull and perhaps an Abbvie shill.
Your logic is ridiculous. You're taking the opinion of your doctor as gospel when this supposed expert isn't even aware of a much superior option for his patients that will soon be available. He should be the one telling you how excited he is. That he's not, to me, says he's not such an expert at all. Regardless he's one doctor so it's purely anecdotal. I'll give you credit for at least stating that at the beginning of your original post.
Lol. That's completely anecdotal based off a discussion with one doctor. Call him a Botox man? That sounds about right to me. Alternatively, he might just be obstinate. Many doctors, even excellent ones, think they know everything, or at least know better than you do. It sounds like he's not patient-first given that he will be giving his patients substandard care. I do agree that word-of-mouth will be less beneficial in therapeutics which could slow the rollout as patients will stick with their doctor's recommendation (even if wrong) rather than seeking the best option they see on social media.
I should add that Daxxify is not yet approved for CD so it makes sense that awareness is low. No attempt has been made yet, obviously, to sell Daxxify for therapeutics. Everybody knows RVNC will need a partner for therapeutic sales.
And who did the R&D? Jake is a NOT a legitimate voice on this board. He is a troll. What's your endgame Jake? If ENTA does get a partnership on EDP-235 are you going to quiet quit this board and disappear?
A new low for Jake's credibility. He has no idea what he's talking about on HCV! That fits with what I've been saying that Jake is no ENTA sage but rather a troll using ENTA as a means to an end. I'm all about hearing opposing viewpoints but this guy has stepped over a line and I'm surprised he has not been banned by the moderator.
I don't normally comment on my own trades but I will have you know Jake that I've done extremely well on ENTA over the years. It could go to $0 now and that would still be true.
If you look back to the March 2020 market panic you'll see that ENTA was essentially unaffected, and that was before the announcement of EDP-235. ENTA had already sold off considerably in 2019 for unrelated reasons. Impossible to say for sure what would happen in a future hypothetical panic but it's not unprecedented that ENTA could be spared, especially after this year's already brutal sell off.
Imo just about everything bad is already priced in. The market sentiment on ENTA can be summed up as basically what Jake the troll posts here.
I don't care to assign probabilities but I think the risk/reward is very much tilted toward the upside. There are many potential catalysts to move the stock higher and it wouldn't take much good news at this point to send the Jakes of the world packing.
At the current price you could more than 5x if ENTA went back to prices it has hit multiple times and as recently as 20ish months ago.
You could just as easily say this is bullish for ENTA if other companies sense the sales opportunity in this market is weak and back off their own efforts.
EDP-235 is the best Covid anti-viral currently known based on actual clinical or real world data. ENTA also already has a follow-on PLpro compound in development.
Covid is not going anywhere and reinfection is common even among previously vaccinated individuals. People I know have recently gotten infected and suffered 2-week plus bouts of illness. Paxlovid is not at all a compelling product for low risk individuals given the complexity, bad taste, and lack of statistical benefit. Most people are interested in feeling better sooner if there is a product that is perceived to work and have low risk. People seek out OTC medicines for the common cold for this very reason.
But Paxlovid hasn't been shown to make low risk patients feel better 1-2 days faster like EDP-235 has! Warnings and interactions impact sentiment beyond people who are actually impacted by the interactions. It has to be frictionless for low risk patients to seek it out.
You're speculating based on no actual knowledge. If you're so confident you must be short ENTA right?
Paxlovid is a hard sell for most people who are at low risk for severe disease given that it hasn't been shown to improve symptoms, is 3 pills twice a day that taste bad, and has many interactions with other medicines.
It would be far easier to convince such a cohort to seek out a superior drug like EDP-235.
I believe this was expected as governments and clinics work through their existing inventory. I'm sure Dew would remember.
Edit: He just posted...
Thanks for your insight!
I agree it will take time for Daxi to grow market share but your earlier comment about having only one shot at launch as informed by Jeuveau's experience doesn't hold for Daxxify. Informed patients will start asking for Daxxify and if a provider doesn't offer it the patient will go elsewhere!
The car analogy isn't very good because a car is a durable good with many considerations. Premium models also cost significantly more to manufacture. Revance has a lot of room to adjust pricing as needed to increase market share.
Also, per your point about dissatisfaction with Abbvie, obviously Revance gives you an alternative as well. How has your experience been dealing with Revance reps?
Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-host-conference-call-august-7-430-pm-et-1
Source? There's been no press release posted on Revance's website.
Exactly. He's speaking out of both sides of his mouth. Jake is troll, nothing more. Some people on this board have given him far too much credit. A broken clock is also right twice a day. The wording of this most recent asinine post reveals his true intentions.
Just to be clear, that image was posted on Instagram by a provider and is not endorsed or affiliated with Revance in any way. I doubt the high powered lawyers will go after a small business for an Instagram post.
https://kristenjacobs.com/
https://www.yelp.com/biz/ooh-la-la-spa-anti-aging-and-wellness-glen-carbon
Btw the question about Daxi on yesterday's Abbvie call was from Terence Flynn with MS who has a $26 equal-weight on RVNC and a $184 overweight on ABBV. Morgan Stanley is a well known shill for some other publicly traded companies.
Don't be silly. For them to make such an announcement now would essentially be saying publicly they will get approval. While I think approval is extremely likely, the last thing RVNC needs to do right now is upset the FDA. Especially given what happened in 2021.
Jake, that is an extremely low quality post. Par for the course for you. Everybody can see the market price. Everybody knows how far away September is.
What are you trying to accomplish? I'm quite sure even you are not dumb enough to be short this stock right now.
You're an EOLS investor so perhaps not entirely objective. EOLS has not exactly been a good investment despite yesterday's surge.
You're missing a crucial difference between EOLS and RVNC. Jeuveau is essentially marketed at providers as a way for them to juice their own profits while delivering similar results to Botox. Jeuveau has no significant benefits over Botox.
Daxxify on the other hand is superior to Botox in multiple ways. Patients are quickly finding this out for themselves. Some patients are misguided by deceitful providers but you can't hide the truth from the majority of patients for very long.
Abbvie's comments on Daxxify's launch strength carry almost no weight. Their comment on patient reactions is asinine but perhaps they're in an echo chamber with their own shills. What I've seen on social media suggests that most patients are thrilled with how superior Daxxify is over Botox and it's living up to the hype.
Put CD aside for a moment. Your points on Nashville assume that the potential buyer already has an aesthetics sales force and the machine RVNC is building to sell Daxi has no value to them. I disagree. You have said yourself that the best sales people in the industry now work for Revance. Building the relationships takes time. A potential buyer will want the entire package.
That's what I thought as well, but the timing of the comments from ABBV are clearly responsible for that drop this morning.
I definitely still think a hedge fund (or somebody) is manipulating the price lower. Whether that's because they heard through the grapevine about a potential raise or they're just bearish about near term sales is impossible to say for sure.
It does seems pretty clear that they will need another raise at some point if a buyout is not going to happen in the next 12ish months.
My counterpoint would be that clinical data is nice but as awareness of how superior Daxxify is to Botox continues to permeate social media, potential buyers may emerge who had not previously considered Revance.
My answer is definitely yes. The machine RVNC is building will be of value to any potential buyer who doesn't already have an aesthetics sales force. With RVNC you're getting more than just the best toxin. I also think the Daxxify (still often called Daxi for short) brand has real value and potential.
Thank you! I just listened. I assume the last toxin launch she's benchmarking Daxxify against was from EOLS? Do you recall their launch strategy?
Her comments about market share probably just confirm what we know about RVNC taking a measured approach to launch. Perhaps sales in the current quarter will disappoint but most long term bulls don't care about one quarter.
On the other hand her comments about patient and provider reactions do not align at all with what I've seen on Instagram and TikTok. It sounds like pure FUD and isn't backed up by any actual data.
Asking Abbvie about Revance is kind of like asking Elon Musk how GM is doing.
I stand corrected, thank you. Was there any more depth to their commentary or just that one comment? I'm sure their figure was true for a moment in time in Q2 but they probably failed to speak to the trajectory.
RVNC has already traded nearly 1M shares in the first hour. Somebody appears intent on preventing the price from rising. This price action helps to validate jmkobers' theory on a raise imo.
That's definitely outside my area of knowledge. There are other people on this board who know better.
I think patients will want the drug because of significant benefits over other toxins and it should mostly sell itself once there's enough awareness. With aesthetics the providers are often out for their own financial interests so Mark and Dustin have to play the game and I think they are.
The lact of approved indications will be a problem for therapeutic reimbursement so I think the proceeds from a potential raise would be more likely spent there than a large therapeutic sales force.
They may also just want to solidify the balance sheet now with the realization that it will take longer to achieve the buyout valuation shareholders deserve.
Or, maybe there's no raise coming and the entire sell off has been trend-following CTA's and hot money fund managers panic buying anything remotely related to AI and dumping everything else.
We'll know more soon one way or another.
Come on Jake. This is below the intelligence level of even your normal post.
Many people don't get vaccinated. Even those who do suffer breakthrough infections.
Jake is no ENTA sage. He's just a troll who doesn't know his facts.
I've been lurking on this board for years. Decided it was time to join the conversation. Can't say the sell-off didn't impact that decision (also to reply to that Jake a-hole). I would have preferred to have gotten a buyout long ago.
I actually agree with you on the reason for the sell-off. Nothing else makes sense. You were right about the last raise so clearly you've got some strong intuition.
What I've seen on Instagram and TikTok is very encouraging. I think Daxi lives up to the hype. The only real negative opinions I've been able to surface stink of the usual ABBV shill talking points.
Where I disagree with you is on the competence of the current management team. I think Mark and Dustin understand the industry and are taking the right approach. Admittedly, it looked bad when Mark said in 2021 that they still expected approval and 3 days later they got a CRL, but I actually believe the mistakes were hangovers from the Joshi and Dan Browne days. Plus, I think Dustin is excellent, and Mark is the one who saw the promise in him.
I'm not sure how quickly sales will ramp, but imo Daxi can achieve a significantly higher terminal market share than I think most analysts have penciled in. Mark and Dan already shown they can execute by ramping filler sales to 10% which was the original market share goal.
I gave up on football a few seasons ago so I can't help you on that last one.
Jake2234: This will be my lost post on this, at least until Jake's next inane post on ENTA.
I will say again, Jake openly admitted that he was here to troll. If he was short he'd be nervous because shorting a microcap biotech is extremely risky. He's not nervous because he's not short.
He's only been right about ENTA as much as a broken clock is right twice a day. Mark my words, if ENTA rebounds, Jake will try and find another name that is in the dumps to troll his intended target with. This is NOT specifically about ENTA.
I don't think so. He has only chosen ENTA as a vehicle to troll one of the users on this board.
He revealed it in this message on the ENTA board, but he quickly edited the message to remove that part. Sadly I did not screenshot it when I had the chance and I suspect few people saw it before he edited it. But I did, so I know.